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BACKGROUND: Tumour size and nodal involvement are the two main prognostic factors in breast cancer (BC). Their impact on the
natural history of BC is not fully captured by analyses that ignore their quantitative nature.
METHOD: Data pertaining to 18159 patients treated with primary surgery: 3661 at the Institut Gustave-Roussy (IGR, France) between
1954 and 1983, and 14498 in the breast cancer registry in the Stockholm–Gotland Health Care region (SG, Sweden) between 1976
and 1999, were collected. The risks of distant metastases (DMs) and of nodal involvement were analysed according to tumour size
with parametric models.
RESULTS: Using SG 1976–1990 as the reference group, relative risks (RRs) for DM were equal to 1.42 (95% CI: 1.29–1.56; Po10
 10)
in IGR and 0.61 (95% CI: 0.55–0.67; Po10
 10) in SG 1991–1999. Differences in tumour size explained the increased risk in IGR
(RR adjusted for tumour size 1.09; 95% CI: 0.99–1.20; P¼0.07), but not the decreased risk in SG 1991–1999 (adjusted RR: 0.63;
95% CI: 0.57–0.69; Po10
 10). The relationship between tumour size and DM risk changed significantly during the 1990s.
CONCLUSION: Early diagnosis is sufficient to explain differences in the prognosis before 1990. After 1990, the use of adjuvant systemic
therapies is the main reason for the reduction in DM.
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In developed countries, the incidence of breast cancer increased
regularly from 1975 to 2000 (Parkin et al, 2001). A decrease in
mortality was first observed in the United States during the 1990s
(Ries et al, 2004). Recent publications by the Cancer Intervention
and Surveillance Modeling Network (CISNET) attributed the
decrease in case fatality to screening and adjuvant treatments
(hormone and chemotherapy) (Berry et al, 2005; CISNET, 2006).
The conclusions were supported by seven different models using
analytical or simulation techniques and including from 6 to 40
parameters. Several models used the decreased mortality observed
in clinical trials (EBCTCG 1998a,b) as model inputs to estimate the
effect of therapies on mortality.
In order to extend the work of the CISNET, we chose a simple
approach based on the most relevant prognostic parameters:
tumour size and axillary lymph node involvement. These
parameters are the cornerstones of the TNM (tumour, the lymph
nodes and metastasis) system and of new prognostic tools such as
Adjuvant! (http://www.adjuvantonline.com) (Ravdin et al, 2001).
We focused on distant metastases instead of mortality in order to
avoid any problem related to the definition of breast cancer
mortality or to changes in mortality patterns in a population. We
used tumour size as a quantitative variable to maximise the use
of the information. Our strategy is based on analyses of the
relationship between tumour size and the probability of distant
metastasis (Koscielny et al, 1984). This strategy was used during
the 1980s to build a simulation model that predicted a roughly 30%
decrease in the incidence of metastases with screening (Koscielny
et al, 1985). These results, which were among the theoretical
arguments used to justify screening (Tubiana and Koscielny,
1990), are actually in keeping with the results of screening trials
(Nystro ¨m et al, 2002).
As the study period spans about 50 years, we also investigated
the effect of the year of treatment and, consequently, of the effect
of changes in management strategies (early detection, introduction
of organised mass screening, adjuvant endocrine or cytotoxic
therapies) on the relationship between tumour size and the risks of
nodal involvement and metastasis.
MATERIALS AND METHODS
Institut Gustave-Roussy database
This database includes 7688 consecutive patients with breast
carcinoma treated at the Institut Gustave-Roussy (IGR; France)
between 1 January 1954 and 31 December 1983. The database was
updated every 2 years and last updated in 2003–2005.
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sStockholm–Gotland Health Care region breast cancer
registry
The Stockholm–Gotland Health Care region (SG) registry
(Sweden) covers a population of about 1 million women (946784
in 1999), and around 1000 new breast cancer cases are now
registered annually. Follow-up is continuously updated. During
the period spanning from 12 April 1976 to 31 December 1999,
21700 breast cancer patients were included. The last follow-up
date was 1 April 2005. The Stockholm mammography screening
programme was started in 1989, inviting women between 50
and 69 years of age to have a mammography at 2-year intervals
(To ¨rnberg et al, 2005).
Patient selection
The only available and reliable measurement of tumour size in the
two databases was the largest diameter measured on the surgical
specimen in patients who had undergone primary surgery. To use
similar information in the two databases, we selected patients
with invasive breast cancer who first underwent surgery and for
whom tumour size and the number of histologically involved
nodes were available. The tumour grade and hormone receptors
were not included in the analyses. Patients with detectable
metastases at diagnosis or patients who had previously been
treated for another cancer were excluded. Thus, 18159 out of
29388 patients present in the two databases were analysed.
Relationship between tumour volume and the proportion
of patients with events
Logistic, complementary log–log and probit regression models
were used to analyse the relationship between tumour size
(a quantitative variable) and qualitative data (axillary node
involvement, metastasis occurrence). The logistic and comple-
mentary log–log regressions (or Cox’s model when time to event
was used as a continuous variable) led, respectively, to odds ratio
and relative risk estimates, which are useful for assessing risks but
not for understanding the mechanisms or the natural history of
the disease. Probit regressions were used to estimate tolerance
distributions, for example, distributions of tumour volume
required to obtain a given proportion of patients with involved
nodes, or a given proportion of patients with detectable metastases
within 5 years of treatment.
The tumour volume was calculated from the largest tumour
diameter assuming spherical lesions. In the regression models,
the quantitative variable used for tumour size was the logarithm
of tumour volume. We analysed two end points: the number of
involved axillary lymph nodes (used as an ordinal variable) and
the occurrence of distant metastases during the 5 years after
treatment.
Axillary nodal involvement was analysed through regres-
sions between tumour size and the number of positive axillary
lymph nodes. The number of sampled nodes was introduced
as a covariate with five categories (1–6, 7–9, 10–14, 15þ and
unknown).
The relationship between tumour size and metastasis occur-
rence was analysed after grouping tumours by diameter in 1-cm
increments. We estimated the 5-year cumulated proportion of
patients with metastases, and the geometric mean tumour size in
each group.
We used the Kaplan–Meier method to estimate the proportions
of patients with distant metastases. Only distant metastases
registered as first events were counted as events. Patients who
experienced a competing event first were censored at the date of
the first event. Deaths were never counted as events: distant
metastases followed by deaths were counted as an event at the time
of the first distant metastasis; patients dying without distant
metastases were censored at death. Local recurrences that occurred
first were not counted as events; patients were censored at the time
of the local recurrence, and we implicitly assumed that their risk
of distant metastases was similar to that of women who had not
experienced a local recurrence.
Dissemination patterns according to the patient’s origin
(IGR vs SG) and the period of treatment
Patients were distributed into three groups as follows (Table 1):
(1) all patients from IGR (IGR 1954–1983); (2) patients treated
in the Stockholm–Gotland region between 1976 and 1990 (SG
1976–1990); and (3) patients treated in the Stockholm–Gotland
region after 1990 (SG 1991–1999). Lymph node involvement
and the 5-year risk of metastases were analysed with respect to
tumour size, assuming a relationship with identical slopes in the
three groups.
The tumour volume corresponding to a 50% 5-year risk of
metastases was calculated in each cohort. The number of involved
nodes was analysed as a function of tumour size, the number of
sampled nodes and the cohort. The tumour volume corresponding
to 50% of tumours with involved nodes was calculated in each
cohort (assuming a number of sampled nodes of between 7 and 9)
and it was used as an indicator of the tumour’s propensity to
invade axillary lymph nodes.
Table 1 Patient and treatment characteristics
IGR
Stockholm (SG)
Period 1954–1983 1976–1990 1991–1999
Number of patients 3661 6778 7720
Age at diagnosis (years) 54 (5 missing data) 61 58
Pre-menopausal (%) 40.9 26.4 28.5
Geometric mean tumour diameter (mm) 22.0 18.0 16.0
Median number of sampled nodes 15.0 7.0 9.0
Number of patients with missing data 5 1361 47
Patients with node-positive disease (%) 56.3 34.6 34.3
Total mastectomy (%) 78 81 46
Postoperative radiotherapy (%) 61 35 59
Adjuvant chemotherapy (%) 2 9 20
Adjuvant endocrine therapy (%)
a 23 23 72
IGR¼Institut Gustave-Roussy; SG¼Stockholm-Gotland Health Care region.
aAt the IGR 1954–1983, adjuvant endocrine therapy was ovarian ablation in pre-menopausal
patients. In Stockholm, it was mostly tamoxifen in postmenopausal patients. No P-values are given because, due to the high number of patients, virtually all the differences are
statistically significant.
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sEvolution of dissemination patterns according to the year
of surgery
The total population (18159 patients) was divided into 18
consecutive cohorts of patients (17 first cohorts including 1000
patients and the last cohort including 1159 patients) with no
distinction between IGR and SG patients. The relationship between
tumour size and the proportion of patients with metastases at
5 years was analysed with probit regression, assuming similar
slopes in all cohorts.
Statistical tests
The distributions of qualitative variables were compared with
w
2 tests and the distributions of quantitative variables with non-
parametric Kruskall–Wallis tests. The proportions of patients
free of distant metastases according to the time since treatment
were compared with log-rank tests. The statistical significance of
the regression parameters was assessed with Wald tests. All the
analyses were carried out using Statistical Analysis System (version
8.2, SAS, Cary, NC, USA) software.
Role of the funding source
This study was carried out by a collaboration between the Institut
Gustave-Roussy (Villejuif, France), the Karolinska Institutet
(Stockholm, Sweden) and the Stockholm–Gotland Breast Cancer
Group. The two institutes funded the sabbatical periods spent by
SK in Stockholm.
RESULTS
The three patient groups differed significantly for almost all study
parameters (Table 1). Patients treated at IGR were about 6 years
younger and consequently more frequently pre-menopausal than
those from the Stockholm area. The major differences in tumour
characteristics among the three groups were with regard to tumour
size and the proportion of node-positive tumours. The most
important therapeutic change was the major increase in the use of
adjuvant endocrine therapy (mainly tamoxifen in postmenopausal
women) from 23% before 1991 to 72% after 1990 (Table 1).
Adjuvant chemotherapy, mostly cyclophosphamide methotrexate
fluorouracil (CMF), was also used with ever-increasing frequency
during the nineties.
Incidence of distant metastases
The incidence of distant metastases according to time since
treatment (Figure 1A) differed significantly between the three
groups (Po10
 10). The hazard functions for distant metastases
were unimodal and the hazards reached a maximum during the
second 1-year interval after treatment (Figure 1B). The hazards of
metastases were roughly proportional between the three groups.
With SG 1976–1990 as the reference group, the relative risks were
equal to 1.42 (95% CI: 1.29–1.56; Po10
 10) in IGR 1954–1983 and
0.61 (95% CI: 0.55–0.67; Po10
 10) in SG 1991–1999.
All the regression models correctly fitted the relationships
between tumour volume and risk of metastases; the differences in
the adjustment to the data were not sufficient to exclude a
particular model (data not shown). The relationships between
tumour volume and the 5-year risk of distant metastases were not
different between IGR 1954–1983 and SG 1976–1990 (Table 2a).
Smaller tumour sizes in the Stockholm–Gotland region were
sufficient to explain the difference in the prognosis between the
two groups. The 5-year risks of distant metastases adjusted for
tumour size were not significantly different (16.2 vs 14.8% for an
18-mm tumour) between the two groups. Similarly, the odds ratio
(logistic model) and relative risks (Cox’s model) for distant
metastases were not different from 1 when adjusted for tumour
size used as a continuous covariate. It should be noted that when
tumour size was categorised with a simple cutoff at 3cm, the odds
ratio and relative risk became significantly different from 1 (last
row of Table 2a).
In contrast, the decrease in the 5-year risk of distant metastases
between SG 1976–1990 and SG 1991–1999 was not explained by
differences in tumour size. In the three regression models, the
relationship between tumour size and the probability of distant
dissemination changed significantly between the two periods in the
Stockholm material (Po10
 10). The logistic regression and Cox
models adjusted for tumour size were also consistent with a highly
significant difference between the two groups (Po10
 10). The
Patient’s group:
SG 1991-1999
SG 1976-1990
IGR 1954-1983
P
r
o
p
o
r
t
i
o
n
 
w
i
t
h
o
u
t
 
m
e
t
a
s
t
a
s
e
s
0.0
0.2
0.4
0.6
0.8
1.0
Years since treatment
H
a
z
a
r
d
 
f
u
n
c
t
i
o
n
 
(
m
e
t
a
s
t
a
s
e
s
)
0.00
0.02
0.04
0.06
0.08
Midpoint of time interval
0 20 15 10 5
02 0 15 10 5
1271 1645 2003 2582 3661
1507 3367 4598 5783 7720
0 0 2200 5575 6778
Patient’s group:
SG 1991-1999
SG 1976-1990
IGR 1954-1983 1271 1645 2003 2582 3661
1507 3367 4598 5783 7720
0 0 2200 5575 6778
Figure 1 Distant metastasis-free rates (A) and corresponding hazard
functions (B) according to patient groups.
Tumour size and breast cancer prognosis
S Koscielny et al
904
British Journal of Cancer (2009) 101(6), 902–907 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
stumour volume required for a 50% rate of metastases at 5 years
was multiplied by 43 in SG 1991–1999 (4900ml) compared with
the other two groups (o300ml).
Nodal involvement
With SG 1976–1990 as the reference group, the risk of nodal
involvement was significantly higher for IGR 1954–1983
(Po10
 10), but was not different for SG 1991–1999 (P¼0.60)
(Table 2b). The tumour volume corresponding to 50% of patients
with nodal involvement during the first Stockholm period was
significantly larger from that in IGR 1954–1983 (P¼0.03) and
smaller than the volume estimated for the second Stockholm
period (P¼0.01). However, even if the differences concerning
axillary node involvement as a function of tumour size were
statistically significant, their clinical importance is limited: the
difference in the risks of nodal involvement adjusted for tumour
size (estimated for an 18-mm tumour diameter) was only 2%
(P¼0.01) between SG 1976–1990 and SG 1991–1999. Similar
results were obtained when logistic regression was applied for
axillary node involvement.
Evolution of metastatic and nodal dissemination patterns
according to the year of surgery
The 5-year probability of metastases decreased regularly according
to the year of surgery (Figure 2A). Overall, the probability of
metastases was divided by 3 between 1954 and 1999. The tumour
volume resulting in 50% of patients with distant metastases at
5 years (Figure 2B) did not vary significantly between 1954 and the
beginning of the 1990s and increased markedly afterwards, when it
was multiplied by a factor of 10 (from about 200ml before 1990 to
more than 2000ml in 1999). This apparent decrease in the capacity
of tumours to generate detectable metastases in the five post-
treatment years contrasts with a stable ability to invade axillary
lymph nodes (Figure 2C).
Comparison between IGR and SG over the 1976–1983
period
We also performed a comparison between IGR and SG that was
limited to the 5057 patients treated during the 1976–1983 period,
which is common to the two centres: 1756 patients in IGR and 3301
in SG. The differences/similarities between these two populations
were the same as that observed in the broader comparisons
between IGR 1954–1983 and SG 1976–1989. The tumour size,
the proportion of patients with involved nodes and the 5-year
proportion of patients with metastases were significantly larger in
IGR 1954–1983 (Po10
 10, Po10
 10 and Po10
 5, respectively),
whereas the relationships between tumour size and axillary lymph
node positivity and 5-year proportion of patients with metastases
were not significantly different. All the conclusions regarding
comparisons between IGR 1954–1983 and SG 1976–1989 are also
valid for those between IGR and SG that were restricted to patients
treated during the 1976–1983 period.
DISCUSSION
This study included patients treated in two European countries,
over a 50-year period. The most striking result is the regular
decrease in the risk of developing distant metastases according to
the year of surgery. For a patient treated in 1999, the risk of
metastases was about one-third than that of a patient treated in the
1960s (Po10
 10). The issue was to determine to what extent this
variation was attributable to differences in tumour malignity, or to
earlier diagnosis or to better treatment strategies. Our main
Table 2a Analysis of 5-year distant metastases according to the origin of the patients and period of surgery
Total (n¼18159 patients)
IGR 1954–1983
(3661)
SG 1976–1990
(6778)
SG 1991–1999
(7720) P-values*
Geometric mean tumour diameter (mm) 22.0 18.0 16.0 o10
 10/o10
 10
Absolute risk of distant metastases at 5 years (95% CI) 20.8% (19.5–22.2) 15.2% (14.4–16.0) 9.5% (8.8–10.2) o10
 10/o10
 10
Relative risks of metastases (95% CI) 1.42 (1.29–1.56) 1 (reference) 0.61 (0.55–0.67) o10
 10/o10
 10
Probit analysis: estimated tumour volume (ml) corresponding
to 50% of patients with metastases at 5 years (diameter mm)
237ml (77mm) 305ml (83mm) 985ml (123mm) 0.07/o10
 10
Probability of metastases for a 18-mm tumour (+) (%) 16.2 14.8 9.5
Odds ratio (logistic regression) adjusted on continuous tumour
size (95% CI)
1.11 (0.99–1.23) 1 (Reference) 0.60 (0.54–0.67) 0.07/o10
 10
Relative risks (Cox’s model) adjusted on continuous tumour
size (95% CI)
1.09 (0.99–1.20) 1 (Reference) 0.63 (0.57–0.69) 0.07/o10
 10
Relative risks (Cox’s model) adjusted on tumour size category
(o30 vs X30mm) (95% CI)
1.29 (1.17–1.41) 1 (Reference) 0.61 (0.55–0.67) 10
 7/o10
 10
IGR¼Institut Gustave-Roussy; SG¼Stockholm-Gotland Health Care region. *P-values: the 1st P-value refers to the IGR 1954–1983 vs SG 1976–1990 comparison, the 2nd to
SG 1976–1990 vs SG 1991–1999. (+) 18mm is the geometric mean tumour diameter in the overall population.
Table 2b Analysis of nodal involvement according to the origin of the patients and period of surgery
Total (n¼18159 patients)
IGR 1954–1983
(n¼3661)
SG 1976–1990
(n¼6778)
SG 1991–1999
(n¼7720) P-values*
Geometric mean tumour diameter (mm) 22.0 18.0 16.0 o10
 10/o10
 10
Patients with node positive disease (%) 56.3 34.6 34.3 o10
 10/0.73
Probit analysis: tumour volume (ml) corresponding to 50% of patients
with involved nodes (diameter mm)
10.7ml (27.4mm) 13.8ml (29.8mm) 17.7ml (32.3mm) 0.03/0.01
Probability of node involvement for an 18-mm tumour (+) (%) 37.9 35.6 33.4
Odds ratio (logistic regression), adjusted on tumour size and the
number of sampled nodes (95% CI)
1.13 (1.03–1.24) 1 (Reference class) 0.91 (0.84–0.98) 0.01/0.01
Footnote see Table 2a.
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sfindings were (a) the constancy of the relationship between tumour
size and nodal involvement, (b) no significant differences in the
relationship between tumour size and the 5-year risk of distant
metastases for IGR 1954–1983 and SG 1976–1990 and (c) a change
in this relationship after 1990 in the Stockholm database.
Constancy of the relationship between tumour volume and
nodal involvement
Nodal involvement was used as a measure of the tumour’s ability
to spread (Carter et al, 1989; Koscielny et al, 1989; Michaelson
et al, 2003a). The tumour volume required to obtain 50% of
patients with involved nodes was deduced from nodal involvement
and tumour size, two parameters that are available before the use
of any adjuvant treatment. We considered that this volume could
not be affected by the use of adjuvant treatments and was a
measure of the intrinsic malignant capacity. Our observations over
50 years suggest a remarkable stability of the malignant capacity of
tumours: the tumour volume required for nodal involvement
increased by o3% yearly over the 50 years covered by the study
(Figure 2C). These data strongly suggest that the decrease in breast
cancer mortality observed in many countries is not due to a
decreased malignant capacity.
Similar relationships between tumour volume and 5-year
risk of distant metastases for IGR 1954–1983 and SG
1976–1990
The risk of metastases was significantly higher in IGR 1954–1983
than in SG 1976–1990 (RR¼1.42; 95% CI: 1.29–1.56; Po10
 10).
However, the relationship between tumour volume and risk of
metastases was not significantly different between the two groups
(P¼0.07), nor was the relationship between tumour volume
and nodal involvement (P¼0.03). When adjusted for tumour size,
the relative risk of metastases was not significantly different
between the two groups (RR¼1.09; 95% CI: 0.99–1.20; P¼0.07).
This finding implies that differences in the initial tumour volume,
related to early diagnosis in SG, explain most of the difference in
prognosis between the two groups of patients.
Early diagnosis and screening
Surprisingly, the highly significant differences in tumour size
at treatment were not related to the screening programmes that
took place in the SG region. The Stockholm trial began in 1981
(Frisell et al, 1997), covering about 25% of the population of
the Stockholm–Gotland region and was converted into a service
screening programme covering the entire region in 1989 (To ¨rnberg
et al, 2006). The superiority of the service screening programme
over the initial screening trial is not perceptible in our data, as the
geometric mean tumour diameter decreased by only 2mm after the
start of the service screening programme. Regardless of the
reasons for the patient participation in screening programmes, our
data show that early diagnosis has a real impact on the reduction
of breast cancer mortality. Our data support screening because it
would not be ethical to be perfectly aware that early diagnosis
reduces cancer mortality without providing a tool for early tumour
detection. Before sending out negative messages, screening
detractors should consider countries where breast cancer mortality
is related to very late detection of tumours, and not only to
slightly earlier treatment due to screening in countries where early
detection is already a reality.
Tumour stage vs tumour size
We found only one study evaluating the impact of early diagnosis
using quantitative estimates of tumour size (Michaelson et al,
2003b). Many other studies used stage (or ranges of tumour size)
95% CI
Risk
95% CI
5
-
Y
e
a
r
 
r
i
s
k
 
o
f
 
m
e
t
a
s
t
a
s
e
s
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0.20
0.22
0.24
0.26
Year of surgery
95% CI
Median
95% CI
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
5
0
%
 
o
f
m
e
t
a
s
t
a
s
e
s
)
10
100
1000
10000
Adjusted for the number of sampled nodes
95% CI
Median
95% CI
V
o
l
u
m
e
 
(
5
0
%
 
n
o
d
e
 
i
n
v
o
l
v
e
m
e
n
t
)
0.1
1.0
10.0
100.0
1950 2000 1990 1980 1970 1960
Year of surgery
1950 2000 1990 1980 1970 1960
Year of surgery
1950 2000 1990 1980 1970 1960
Figure 2 Variations according to the year of surgery for the whole
population. (A) The 5-year proportion of patients with metastases
decreases regularly with the year of surgery from more than 20% in the
1950–1960s to o8% in 1999. (B) The tumour volume corresponding to
50% of patients with distant metastases during the first 5 years remains
stable up to the beginning of the 1990s. During this period, differences in
tumour size at treatment are sufficient to explain the decrease in the risk of
metastases. After 1990, the tumour volume corresponding to 50% of
patients with metastases increased rapidly from about 200ml in 1990 to
2000ml in 1999. During this period, the amount of tumour necessary for
metastatic dissemination apparently increased. The reason is either a
reduced metastatic potential of the tumours or a decreased viability of the
metastases. (C) There was no marked change in the year of treatment in
tumour volume corresponding to 50% of patients with involved axillary
nodes. The capacity of tumours to involve lymph nodes was almost
unchanged from 1954 to 1999. This observation contradicts the hypothesis
of a reduction in the metastatic potential of tumours after 1990. Curves are
displayed with the 95% confidence intervals.
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with caution because they are subject to a stage migration bias. This
bias results from better detection of tumours, which increases the
prevalence of good prognosis tumours (migration from the set of
undetectable to the set of good prognosis tumours). As these
additional tumours have a better prognosis than the previous group
of good prognosis tumours, the overall prognosis of the latter group
is improved. The first consequence of stage migration is that it alters
the prognostic meaning of the stage. The way to overcome this bias is
to use quantitative data instead of the qualitative stage. To illustrate
this (Table 2a), the 5-year relative risk of metastasis comparing IGR
1954–1983 with SG 1984–1990, adjusted for the tumour size, was
equal to 1.09 (95% CI: 0.99–1.20; P¼0.07), whereas the relative risk
adjusted for the tumour size category (cutoff at 3cm) was equal to
1.29 (95% CI: 1.17–1.41; P¼10
 7). This example emphasises the
importance of analyses using quantitative data and suggests that
some recent results, such as a significant independent effect of
mammography, observed by Shen et al (2005) might be, at least
partially, a consequence of stage migration.
Improvement of prognosis after 1990
The difference between the two consecutive groups of patients
from the Stockholm–Gotland region (SG 1976–1990 and SG
1991–1999) was not explained by differences in the initial tumour
volume, or by a change in the intrinsic malignity of tumours.
This difference can only be attributed to a decrease in the viability
of metastases due to adjuvant therapy. The more frequent use
of endocrine therapy – mostly tamoxifen– which increased from
o20% to about 80% in the few years after 1990 (Kemetli et al,
2009) is the most plausible single explanation for our observations.
Further analyses are needed to evaluate the real impact of adjuvant
chemotherapy at the population level and the impact of changes in
the treatment strategy such as the prolonged duration of tamoxifen
administration (in 1996), the use of anthracyclines (1999) and,
more recently, the introduction of taxanes. A detailed study of
these adjuvant treatments would necessitate extending the study
population to patients treated after 1999.
In conclusion, our results support the conclusions of the
CISNET group and extend their findings. In our clinical series,
early diagnosis is sufficient to explain the differences in the
prognosis before 1990. After 1990, the generalisation of adjuvant
systemic therapy, mostly tamoxifen, is the main reason for
improved disease control and better use of adjuvant chemotherapy
is likely to improve outcomes further.
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